Device & Drug Revenue Forecasting

inThought Labs

While some companies develop their own detailed forecasts, many understand the value in obtaining an independent third-party point of view on the revenue potential for drugs in a therapeutic area. By utilizing our device and drug revenue forecasts, you will obtain an objective and unbiased projection of the commercial potential of those assets. This powerful information will change your perception or confirm what you already know, allowing you to move forward with a strategy.

Do You Need Forecasting?

The costs of developing new compounds and devices are steep. Before you invest your resources in an asset that may not provide the returns you anticipate, ensure you have the most robust market data and analysis. Our team can help you gain all the pertinent information and provide critical forecasting to inform your strategies.

How It Works

For each indication of each pipeline and marketed drug, inThought will develop a revenue forecast that includes historical data for the past three years and projects seven years in the future. Forecasts will be delivered in an editable Excel format and kept up to date for one year based on results, events, and competitive threat changes.

Our Forecasting Models

Models are developed for a given therapeutic area based on the addressable patient population. This allows for detailed assessment of a compound’s real or potential competitive landscape. Epidemiological considerations include estimates of disease incidence, prevalence, growth rates, and death rates. Models are developed separately for the U.S., Europe, and Japan.

Drug revenue models look seven years into the future and three years into the past.

Device revenue models project three to five years forward and three years back.

For developmental agents, the revenue forecast assumes the drug or device is approved. Risk adjusted valuations can be developed by multiplying the revenue potential—if approved—by the probability of approval as assessed by the inThought Approvability Index.

 

inThought Research empowers biopharma leaders with comprehensive strategic insights. We combine Wall Street financial acumen and swiftness, scientific expertise, and advanced AI analytics to navigate the complex landscape of drug development.

Linkedin
Quick Links
Get In Touch
Our Family Of Companies​
inThought Labs logo

Privacy Policy

Terms of Service

Vulnerability

© 2024 inThought Research. All Rights Reserved.

Contact us

Learn how inThought Labs can simplify your life and empower your team with expert consultants and our cloud-based system, inVision.

Chris Martin

President

As the president of inThought Labs, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.

 

With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.

 

Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.